Department of Diagnostic Pathology, Kurume University Hospital, Kurume 830-0011, Japan.
Hum Pathol. 2010 Jul;41(7):951-9. doi: 10.1016/j.humpath.2009.12.007. Epub 2010 Mar 17.
Patients with non-small cell lung cancer harboring mutations in the epidermal growth factor receptor gene, including delE746-A750 and L858R, are highly sensitive to therapy with epidermal growth factor receptor-targeting drugs, such as gefitinib and erlotinib, in comparison with those harboring wild-type epidermal growth factor receptor. It remains unclear how such epidermal growth factor receptor mutations are induced. In this study, we examined whether 8-hydroxy-2'-deoxyguanosine, a representative oxygen nucleotide of DNA, could play a role in activating mutations of the epidermal growth factor receptor gene and also whether Y-box binding protein-1 and 8-oxoguanine DNA glycosylase that are involved in repair of oxidative stimuli-induced DNA damages could play any role in epidermal growth factor receptor activating mutations. Immunohistochemistry was used to evaluate the expression of 8-hydroxy-2'-deoxyguanosine, Y-box binding protein-1, and 8-oxoguanine DNA glycosylase in patients with non-small cell lung cancer (N = 170). We analyzed mutations of delE746-A750 and L858R in the epidermal growth factor receptor gene using peptide nucleic acid-locked nucleic acid polymerase chain reaction clamping. In non-small cell lung cancer patients, nuclear 8-hydroxy-2'-deoxyguanosine expression was strongly associated with these epidermal growth factor receptor mutations. Furthermore, nuclear expression of Y-box binding protein-1 was inversely associated with epidermal growth factor receptor mutations; but nuclear expression of 8-oxoguanine DNA glycosylase was not. Among 51 patients who were treated with gefitinib, progression-free survival was substantially better when 8-hydroxy-2'-deoxyguanosine expression was positive, when epidermal growth factor receptor mutations were present, and when nuclear Y-box binding protein-1 expression was negative. Thus, activating mutations of the epidermal growth factor receptor gene in non-small cell lung cancer were closely associated with a decrease in the damage repair process for 8-hydroxy-2'-deoxyguanosine in oxidized DNA.
患有非小细胞肺癌并带有表皮生长因子受体基因突变的患者,包括 delE746-A750 和 L858R,对表皮生长因子受体靶向药物治疗(如吉非替尼和厄洛替尼)非常敏感,而带有野生型表皮生长因子受体的患者则不敏感。目前尚不清楚这些表皮生长因子受体突变是如何诱导的。在这项研究中,我们研究了 8-羟基-2'-脱氧鸟苷(一种 DNA 的代表性氧核苷酸)是否可以在激活表皮生长因子受体基因突变中发挥作用,以及是否参与修复氧化应激诱导的 DNA 损伤的 Y 盒结合蛋白-1 和 8-氧鸟嘌呤 DNA 糖基化酶在表皮生长因子受体激活突变中发挥作用。免疫组织化学用于评估非小细胞肺癌患者(N = 170)中 8-羟基-2'-脱氧鸟苷、Y 盒结合蛋白-1 和 8-氧鸟嘌呤 DNA 糖基化酶的表达。我们使用肽核酸-锁定核酸聚合酶链反应夹心法分析表皮生长因子受体基因中 delE746-A750 和 L858R 的突变。在非小细胞肺癌患者中,核 8-羟基-2'-脱氧鸟苷的表达与这些表皮生长因子受体突变强烈相关。此外,Y 盒结合蛋白-1 的核表达与表皮生长因子受体突变呈负相关;但 8-氧鸟嘌呤 DNA 糖基化酶的核表达则没有。在 51 名接受吉非替尼治疗的患者中,当 8-羟基-2'-脱氧鸟苷表达阳性、表皮生长因子受体突变存在且核 Y 盒结合蛋白-1 表达阴性时,无进展生存期明显更长。因此,非小细胞肺癌中表皮生长因子受体基因的激活突变与氧化 DNA 中 8-羟基-2'-脱氧鸟苷的损伤修复过程减少密切相关。